STORM: A randomized phase II Trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases
Ongoing - recruitment closed · 2019 until 2025
Putora Paul Martin
To compare metastases-free survival (MFS) between metastasis-directed therapy and metastases-directed therapy with whole pelvis radiotherapy for oligorecurrent nodal prostate cancer.
Target: 178 Patients